Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Trevena Inc (TRVN)

Trevena Inc (TRVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 163,987
  • Shares Outstanding, K 107,181
  • Annual Sales, $ 30 K
  • Annual Income, $ -24,870 K
  • 60-Month Beta 2.75
  • Price/Sales 5,462.77
  • Price/Cash Flow N/A
  • Price/Book 5.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +25.41%
on 06/04/20
1.9050 -19.69%
on 06/23/20
+0.1600 (+11.68%)
since 06/02/20
3-Month
0.4600 +232.61%
on 04/06/20
1.9050 -19.69%
on 06/23/20
+1.0270 (+204.17%)
since 04/02/20
52-Week
0.4600 +232.61%
on 04/06/20
1.9050 -19.69%
on 06/23/20
+0.5100 (+50.00%)
since 07/02/19

Most Recent Stories

More News
Company News for June 3, 2020

Companies in the news are: DCI, TENX, TRVN, BHTG

DCI : 46.23 (+1.92%)
TRVN : 1.5300 (-3.16%)
TENX : 0.9027 (+0.30%)
BHTG : 1.9000 (-7.32%)
Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the...

TRVN : 1.5300 (-3.16%)
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

--

TRVN : 1.5300 (-3.16%)
Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?

Is (TRVN) Outperforming Other Medical Stocks This Year?

TRVN : 1.5300 (-3.16%)
Thinking about buying stock in TOP Ships, General Electric, Oncolytics Biotech, Trevena, or Minerva Neurosciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, GE, ONCY, TRVN, and NERV.

GE : 6.82 (+1.19%)
NERV : 3.56 (-5.57%)
TRVN : 1.5300 (-3.16%)
Thinking about buying stock in Sorrento Therapeutics, Chesapeake Energy Corp, Trevena, Delta Air Lines, or Royal Caribbean Cruises?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, CHK, TRVN, DAL, and RCL.

CHK : 11.85 (-7.28%)
DAL : 27.72 (+0.07%)
RCL : 49.51 (-2.60%)
SRNE : 6.85 (-1.15%)
TRVN : 1.5300 (-3.16%)
Trevena: 1Q Earnings Snapshot

CHESTERBROOK, Pa. (AP) _ Trevena Inc. (TRVN) on Thursday reported a loss of $5.7 million in its first quarter.

TRVN : 1.5300 (-3.16%)
Trevena Reports First Quarter 2020 Results

Trevena Reports First Quarter 2020 Results

TRVN : 1.5300 (-3.16%)
Has Trevena, Inc. (TRVN) Outpaced Other Medical Stocks This Year?

Is (TRVN) Outperforming Other Medical Stocks This Year?

TRVN : 1.5300 (-3.16%)
Trevena to Release First Quarter 2020 Financial Results on May 7, 2020

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that...

TRVN : 1.5300 (-3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade TRVN with:

Business Summary

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of...

See More

Key Turning Points

2nd Resistance Point 1.6634
1st Resistance Point 1.5967
Last Price 1.5300
1st Support Level 1.4866
2nd Support Level 1.4432

See More

52-Week High 1.9050
Last Price 1.5300
Fibonacci 61.8% 1.3530
Fibonacci 50% 1.1825
Fibonacci 38.2% 1.0120
52-Week Low 0.4600

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar